Physician profile
Jonathan M Powell
NPI 1043620719
$11,197.69
in general payments reported to CMS, 2019-2025
39 companies · $2,698 in 2025
The $2,698 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $718 · 2021: $1,250 · 2022: $1,590 · 2023: $1,817 · 2024: $2,202 · 2025: $2,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,337 · Travel and Lodging: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,337.48 |
| Travel and Lodging | $379.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,399.28 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $1,215.44 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $968.66 | 2019-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Heartflow, INC. | $725.71 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $694.12 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $663.22 | 2021-2025 | Jardiance |
| Amgen INC. | $638.64 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $545.82 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $475.67 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $452.46 | 2023-2025 | Aurora Ev-Icd Mri Surescan, Linq II, Cobalt Dr Mri Surescan |
| Merck Sharp & Dohme LLC | $320.28 | 2022-2025 | Verquvo, Capvaxive |
| Abiomed | $277.31 | 2022-2025 | |
| Pfizer INC. | $259.61 | 2019-2025 | |
| Scpharmaceuticals INC. | $239.79 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $227.68 | 2023-2024 | Inpefa |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $225.33 | 2019-2025 | Ensite Precision, Aveir, Amplatzer Amulet |
| Astellas Pharma US INC | $210.71 | 2019-2020 | |
| Inari Medical, INC. | $188.74 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Esperion Therapeutics, INC. | $184.26 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $152.10 | 2024-2025 | Ozempic |
| Philips North America LLC | $147.88 | 2022-2024 | (Ck4) Mcot |
| Bayer Healthcare Pharmaceuticals INC. | $134.93 | 2024-2025 | |
| Lantheus Medical Imaging, INC. | $125.84 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $124.84 | 2021-2024 | |
| Angiodynamics, INC. | $100.00 | 2024 | Alphavac |
| Kiniksa Pharmaceuticals International, Plc | $87.33 | 2024 | Arcalyst |
| Chiesi USA, INC. | $80.46 | 2019 | |
| Atricure, INC. | $69.84 | 2022 | |
| Baxter Healthcare | $45.59 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Kestra Medical Technology Services, INC. | $44.29 | 2025 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $35.74 | 2019 | |
| Vital Connect, INC | $24.40 | 2024 | Vitalpatch Rtm |
| Kowa Pharmaceuticals America, INC. | $24.39 | 2021 | |
| Akcea Therapeutics, INC. | $21.28 | 2019 | |
| Daiichi Sankyo INC. | $19.40 | 2023 | Injectafer |
| Amarin Pharma, INC. | $17.96 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.37 | 2021 | |
| Lundbeck LLC | $13.32 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.